<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0420</journal-id>
<journal-title><![CDATA[Revista Uruguaya de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Urug.Cardiol.]]></abbrev-journal-title>
<issn>1688-0420</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Uruguaya de Cardiología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-04202017000200121</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Fibrinolíticos en el infarto agudo de miocardio. Análisis de una cohorte uruguaya en un período de cuatro años]]></article-title>
<article-title xml:lang="en"><![CDATA[Fibrinolytics in acute myocardial infarction.Analysis of an uruguayan cohort in a four years period]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[Frank]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Sanatorio Cantegril  ]]></institution>
<addr-line><![CDATA[Maldonado ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2017</year>
</pub-date>
<volume>32</volume>
<numero>2</numero>
<fpage>121</fpage>
<lpage>131</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-04202017000200121&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-04202017000200121&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-04202017000200121&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  el tratamiento fibrinolítico (FBL) en el infarto agudo de miocardio con elevación del ST (IAMCEST) se realiza en Uruguay desde hace más de 30 años. Dado que el acceso a angioplastia primaria está restringido a Montevideo, los FBL siguen siendo el método de reperfusión para muchos pacientes. Desde el año 2011 el Fondo Nacional de Recursos (FNR) ofrece la cobertura financiera del tratamiento FBL. Existe escasa información actualizada sobre su empleo en nuestro medio.  Objetivo:  conocer el estado actual del uso de tratamiento FBL bajo cobertura del FNR, el proceso asistencial y los resultados obtenidos con el mismo.  Método:  estudio retrospectivo, observacional, que analiza una cohorte de pacientes con IAMCEST a quienes se les adminstró FBL financiados por el FNR entre el 1º de julio de 2011 y el 30 de junio de 2015. Se estudiaron de forma anónima factores demográficos, cobertura asistencial, características clínicas, tiempos asistenciales al tratamiento, signos clínicos de reperfusión, realización de cineangiocoronariografía (CACG), tratamiento coadyuvante, complicaciones intrahospitalarias y mortalidad.  Resultados:  se incluyeron 841 pacientes con IAMCEST que fueron tratados con FBL. La edad media fue de 62,6 años (rango 23-95 años), 74,2% era de sexo masculino. Cobertura asistencial pública 23,5% y privada 76,5%. Se utilizó estreptoquinasa (SK) en 52,9% y tenecteplase (TNK) en 47,1%. El tiempo medio entre el inicio de síntomas y el primer contacto médico (PCM) fue de 128 minutos. El tiempo medio PCM-ingreso a puerta fue de 78 minutos y el tiempo puerta-aguja de 77 minutos. Montevideo y tres departamentos cercanos presentaron las tasas más bajas de uso de FBL, el 97,2% fue tratado en el interior del país. Tuvo criterio electrocardiográfico de reperfusión a los 90 minutos, el 54,1%. Se presentó sangrado del sistema nervioso central (SNC) en 0,8%, sangrado digestivo en 0,5% y otros sangrados que requirieron transfusión en 0,6%. El primer día se realizó CACG en el 37,8% de los pacientes (32,8% del grupo SK y 43,5% del grupo TNK, p=0,001), y a los 30 días en 65% (60,6% del grupo SK y 69,7% del grupo TNK, p=0,002). La mortalidad en el primer día fue 5,1%, a los 30 días 10,9% y al año 14,3%, sin diferencia significativa entre los tratados con SK o TNK.  Conclusiones:  la tasa de uso de FBL en el IAMCEST en Uruguay es baja y aproximadamente la mitad se realizan bajo cobertura del FNR. Existen diferencias regionales e inequidad según la cobertura asistencial. Los tiempos al tratamiento son prolongados y están lejos de las pautas internacionales. Se realizó CACG dentro de los 30 días a casi dos tercios de los pacientes, pero solo a 37,8% en las primeras 24 horas. La mortalidad de esta serie es comparable con registros internacionales.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Summary  Introduction:  fibrinolytic (FBL) treatment in ST-Elevation Myocardial Infarction (STEMI) has been performed in Uruguay for more than 30 years. Considering that access to primary angioplasty is restricted to Montevideo, FBL remain the reperfusion method for many patients. Since 2011, Fondo Nacional de Recursos (FNR) offers the financial coverage of the FBL treatment. There is limited updated information on the use of FBL in our country.  Objective:  to know the current state of the use of FBL treatment under FNR coverage, the care process and the results obtained with it.  Method:  retrospective, observational study analyzing a cohort of patients with STEMI who were administered FBL funded by the FNR between 1st July 2011 and 30th June 2015. Demographic factors, health care coverage, clinical features, treatment times, clinical signs of reperfusion, cineangiocoronariography (CACG), adjuvant treatment, intrahospital complications and mortality, were studied anonymously.  Results:  were included 841 patients with STEMI who were treated with FBL. The mean age was 62,6 years (range 23-95 years), 74,2% were male. Public health care coverage 23.5% and private 76.5%. Streptokinase (SK) was used in 52,9% and tenecteplase (TNK) in 47,1%. The mean time between the onset of symptoms and the first medical contact (FMC) was 128 min. The mean time between FMC and emergency admission was 78 minutes and door to needle time was 77 minutes. Montevideo and three nearby departments presented the lowest rates of FBL use, 97.2% were treated in another city outside the capital. The 54,1% had electrocardiographic reperfusion criteria at 90 minutes. Central nervous system bleeding occurred in 0,8%, digestive bleeding in 0.5% and other bleeds requiring transfusion in 0.6%. On the first day, CACG was performed in 37,8% of the patients (32,8% in the SK group and 43,5% in the TNK group, p = 0,001), and at 30 days in 64,9% (60,6% % Of SK group and 69,7% of TNK group, p = 0,002). Mortality on the first day was 5,1%, at 30 days 10.9% and 14,3% at the year, with no significant difference between those treated with SK or TNK.  Conclusions:  the FBL use rate at STEMI in Uruguay is low and approximately half is done under FNR coverage. There are regional differences and inequity according to health care coverage. Treatment times are prolonged and far from international guidelines. CACG was performed within 30 days in almost two thirds of patients, but only 37,8% in the first 24 hours. Mortality in this series is comparable with international registries.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[terapia trombolítica]]></kwd>
<kwd lng="es"><![CDATA[infarto del miocardio]]></kwd>
<kwd lng="es"><![CDATA[cineangiocoronariografía]]></kwd>
<kwd lng="en"><![CDATA[thrombolytic therapy]]></kwd>
<kwd lng="en"><![CDATA[myocardial infarction]]></kwd>
<kwd lng="en"><![CDATA[cineangiocoronariography]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<collab>Fibrinolytic Therapy Trialists' Collaborative Group</collab>
<article-title xml:lang=""><![CDATA[Indications for fibrinolytic therapy in suspected acute myocardial infarction collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1994</year>
<volume>343</volume>
<numero>8893</numero>
<issue>8893</issue>
<page-range>311-22</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keeley]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Boura]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Grines]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction a quantitative review of 23 randomised trials]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2003</year>
<volume>361</volume>
<numero>9351</numero>
<issue>9351</issue>
<page-range>13-20</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[Nielsen]]></surname>
<given-names><![CDATA[TT]]></given-names>
</name>
<name>
<surname><![CDATA[Rasmussen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Thuesen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kelbaek]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Thayssen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction]]></article-title>
<collab>DANAMI-2 Investigators</collab>
<source><![CDATA[N Engl J Med]]></source>
<year>2003</year>
<volume>349</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>733-42</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<collab>O'Gara PT.Kushner FG.Ascheim DD.Casey DE Jr.Chung MK.de Lemos JA</collab>
<article-title xml:lang=""><![CDATA[2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2013</year>
<volume>127</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>e362-425</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2012</year>
<volume>33</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>2569-619</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<collab>Sociedad Uruguaya de Cardiología</collab>
<article-title xml:lang=""><![CDATA[Hospital de Clínicas, Departamento Clínico de Medicina Consenso uruguayo de manejo del infarto agudo de miocardio con elevación del segmento ST]]></article-title>
<source><![CDATA[Rev Urug Cardiol]]></source>
<year>2006</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>48-95</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lluberas]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Buitrón]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Senra]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fibrinolíticos por vía sistémica en el infarto agudo de miocardio experiencia inicial]]></article-title>
<source><![CDATA[Rev Med Urug]]></source>
<year>1986</year>
<volume>2</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>85-9</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grupo]]></surname>
<given-names><![CDATA[EMUFI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudio Multicéntrico Uruguayo de Fibrinolíticos en el Infarto (EMUFI)]]></article-title>
<source><![CDATA[Rev Urug Cardiol]]></source>
<year>1993</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>16-20</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<collab>Instituto Nacional de Estadística</collab>
<source><![CDATA[Censos 2011]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
<publisher-name><![CDATA[INE]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pouso]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Viana]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspectos epidemiológicos del infarto agudo de miocardio en Montevideo un análisis retrospectivo]]></article-title>
<source><![CDATA[Rev Urug Cardiol]]></source>
<year>1989</year>
<volume>4</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>a4-10</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sebrié]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Sandoya]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bianco]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hyland]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cummings]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Glantz]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hospital admissions for acute myocardial infarction before and after implementation of a comprehensive smoke-free policy in Uruguay experience through 2010]]></article-title>
<source><![CDATA[Tob Control]]></source>
<year>2014</year>
<volume>23</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>471-2</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<collab>ISIS-4 Collaborative Group</collab>
<article-title xml:lang=""><![CDATA[ISIS-4 a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1995</year>
<volume>345</volume>
<numero>8951</numero>
<issue>8951</issue>
<page-range>669-85</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boersma]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Maas]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Deckers]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Simoons]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early thrombolytic treatment in acute myocardial infarction reappraisal of the golden hour]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1996</year>
<volume>348</volume>
<numero>9030</numero>
<issue>9030</issue>
<page-range>771-5</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sandoya]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kuster]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Layerle]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Arambillete]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Programa de Infarto Agudo de Miocardio (PIAM)]]></article-title>
<source><![CDATA[Rev Urug Cardiol]]></source>
<year>2010</year>
<volume>25</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>217-25</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Niggemeyer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Proyecto de coordinación nacional para diagnóstico, valoración y tratamiento de los síndromes coronarios agudos en Uruguay]]></article-title>
<source><![CDATA[Rev Urug Cardiol]]></source>
<year>2013</year>
<volume>28</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>412-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Junker]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento fibrinolítico en el infarto agudo de miocardio]]></article-title>
<source><![CDATA[Rev Urug Cardiol]]></source>
<year>2013</year>
<volume>28</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>430-6</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<collab>Instituto Nacional de Estadística</collab>
<source><![CDATA[Uruguay en cifras 2009]]></source>
<year>2009</year>
<publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
<publisher-name><![CDATA[INE]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mayol]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Perna]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Albornoz]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Angioplastia en el infarto agudo de miocardio dentro de las 24 horas de evolución análisis de la casuística uruguaya 2004-2012]]></article-title>
<source><![CDATA[Rev Urug Cardiol]]></source>
<year>2014</year>
<volume>29</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>6-16</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cardoso]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Arambillete]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uso de fibrinolíticos en el ambiente extrahospitalario en el síndrome coronario agudo con ST elevado Experiencia en el Departamento de Rocha]]></article-title>
<source><![CDATA[Pac Crít]]></source>
<year>2010</year>
<volume>18</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>43-8</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gambogi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Baldizzoni]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Saona]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Niggemeyer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wald]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Nigro]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectividad de un programa de prevención secundaria cardiovascular en Uruguay]]></article-title>
<source><![CDATA[Rev Med Urug]]></source>
<year>2013</year>
<volume>29</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>74-84</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vázquez]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Burdiat]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alonso P, Sandoya E, Tejada J Control del riesgo cardiovascular postinternación en pacientes coronarios]]></article-title>
<source><![CDATA[Rev Urug Cardiol]]></source>
<year>2011</year>
<volume>26</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>108-14</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<collab>GUSTO</collab>
<article-title xml:lang=""><![CDATA[Investigators An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1993</year>
<volume>329</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>673-82</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<collab>Assessment of the Safety and Efficacy of a New Thrombolytic Investigators</collab>
<article-title xml:lang=""><![CDATA[Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction the ASSENT-2 double-blind randomized trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1999</year>
<volume>354</volume>
<numero>9180</numero>
<issue>9180</issue>
<page-range>716-22</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Steg]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Goldberg]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gore]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Eagle]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Flather]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[GRACE Investigators]]></surname>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE)]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2002</year>
<volume>90</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>358-63</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hasdai]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Behar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wallentin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Danchin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Gitt]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Boersma]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS)]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2002</year>
<volume>23</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1190-201</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
